Environmental, Social And Governance Report

Overview

The report presents Ascentage Pharma's 2022 sustainability performance across its global group and subsidiaries. The company highlights RMB 743.1 million in annual R&D investment, nine type 1 small-molecule candidates in clinical development, and more than 40 Phase I/II clinical studies. Environmental disclosures include 5,407.99 tCO2e of total greenhouse gas emissions and goals to reduce carbon emissions by 50% from peak value by 2040. The workforce comprised 580 full-time staff, with a 100% employee training rate and average training hours of 8.94 hours.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2022
Period: 1 January 2022 – 31 December 2022
Publication date: 22 March 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis
Matrix

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services